A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/00 (2006.01)
Patent
CA 2740155
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is an adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.
L'invention concerne des compositions et des systèmes pour administrer des nanovéhicules à des cellules du système immunitaire. L'invention concerne des nanovéhicules capables de stimuler une réponse immunitaire dans des lymphocytes T et/ou dans des lymphocytes B. L'invention concerne des nanovéhicules qui comportent une surface présentant des caractéristiques immunitaires et une fraction immunostimulatoire. Dans certains modes de réalisation, le groupe immunostimulatoire est un adjuvant. L'invention concerne des compositions pharmaceutiques comportant des nanovéhicules de la présente invention. L'invention concerne des procédés de conception, de fabrication et d'utilisation des nanovéhicules de l'invention et des compositions pharmaceutiques de ceux-ci.
Alexis Frank
Basto Pamela
Farokhzad Omid C.
Iannacone Matteo
Langer Robert
Massachusetts Institute Of Technology
President And Fellows Of Harvard College
Smart & Biggar
The Brigham And Women's Hospital Inc.
LandOfFree
Adjuvant incorporation in immunonanotherapeutics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adjuvant incorporation in immunonanotherapeutics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adjuvant incorporation in immunonanotherapeutics will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1633544